Prosecution Insights
Last updated: July 17, 2026
Application No. 18/370,733

Laser System and Method for Detecting and Processing Information

Non-Final OA §102§103§112
Filed
Sep 20, 2023
Priority
Sep 23, 2022 — EU 22197529.5 +2 more
Examiner
FARAH, AHMED M
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Terra Quantum AG
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
7m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
1047 granted / 1330 resolved
+8.7% vs TC avg
Strong +19% interview lift
Without
With
+19.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
15 currently pending
Career history
1343
Total Applications
across all art units

Statute-Specific Performance

§101
2.9%
-37.1% vs TC avg
§103
46.5%
+6.5% vs TC avg
§102
15.9%
-24.1% vs TC avg
§112
25.0%
-15.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1330 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of invention I (claims 1-13) in the reply filed on 02/2026 is acknowledged. Claims 14-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 02/20/2026. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 12 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 12 recites the feedback controller comprises and/or is coupled to a high-performance computer. The scope of the limitation “high-performance computer’ cannot be determined from the claim language or the specification and, therefore renders the claim indefinite. Appropriate correction is required. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-3, 7-9 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Shaddock, Pub. No. US 2003/0109907 (hereinafter “Shaddock”). Regarding claim 1, Shaddock discloses a laser system suitable for changing an intraocular pressure (IOP) of an eye (see the abstract, par. 0005 and Fig. 5), the laser system comprising: a laser source 25; a feedback controller 55 configured to regulate a dosimetry of the laser source to produce spatially and/or temporally modulated laser light (par. 0020 [“the invention includes an optional dosimetry control system for terminating or controlling energy delivery based on feedback signal from a temperature sensor array”]), see pars. 0024 and 0068; a first optical delivery element/optical fibers 40 configured to guide the spatially and/or temporally modulated laser light to irradiate a first area on the eye (Fig. 7, par. 0051); and a detecting element configured to detect one or more physical, chemical, mechanical and/or structural characteristics in a second area on the eye in a real-time during the change of the IOP (sensors 57, see Figs. 6, 8, and par. 0056); wherein the feedback controller is configured to regulate the dosimetry of the laser source in a real-time based on the real-time detected information pertaining to the one or more physical, chemical, mechanical and/or structural characteristics in the second area (par. 0068, note that the sensors 57 measure temperature at locations not coinciding with the locations delivered to laser radiation). Regarding claim 2, the first area comprises a part on the sclera of the eye (abstract [“The apparatus includes; (I) a working end geometry for contacting the anterior surface of the sclera and cornea to insure that a laser emission reaches the trabecular meshwork from a particular location on the anterior surface of the sclera”]), wherein the laser source is regulated to modify a porous structure on the sclera. Regarding claims 3 and 7-9, the recited claims language are directed to intended use and do not incorporate additional features or limitations in combination with the features of any claim or claims to which they refer. Regarding claim 7, the claim recites the laser source is regulated to activate one or more cells on the ciliary body. However it does not teach a specific laser light (e.g., regulated dosimetry/ dose of the laser source to activate one or more cells on the ciliary body) /parameters to activate one or more cells on the ciliary body (note: specification par. [0058] teaches [“Each of the laser sources 101 may further be assigned to different tasks. For example, during a treatment, a first laser source 101 may generate modulated laser light to close pores on the sclera, while a second laser source 101 may generate a modulated laser light to activate the ciliary body regeneration]). Furthermore, Shaddock teaches the modulated laser light is suitable for achieving and/or maintaining a first temperature range and/or a second temperature range in the first area as claimed (par. 0022 [“For the proposed method of trabecular bio-stimulation, the targeted region is elevated in temperature to a range between about 40.degree. C. to 55.degree. C. for a period of time ranging from about 1 second to 120 seconds or more. More precisely, the desired range would be between about 40.degree. C. to 50.degree. C. for such time periods.”]), wherein the modulate laser light (pars. 0014, 0022,0057) suitable for generating thermomechanical wave, which can propagate to a third are outside the first area as broadly as claimed. Regarding claim 12, Shaddock teaches the controller of the system includes dosimetry control system 55 and optional beam sequence controller 59, which computer controllers adapted to operate in cooperation to control the power of the laser energy (par. 0057). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or no obviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim 4 is rejected under 35 U.S.C. 103 as being unpatentable over Shaddock in view of Baer veldt et al., Pub. No. 2002/0111608 (hereinafter “Baer veldt”). Shaddock does not teach the feedback controller is configured to calculate a flow rate of fluid through the porous structure on the sclera as claimed. Baer veldt discloses a minimally invasive glaucoma surgical instrument and method, the system comprising a software and feedback to a controller, which result in full process control configured to determine fluid flow rate and pressure during the treatment [Par. 0178] to determine when ablation is completed through time, temperature and/or impedance.) It would have been obvious to one of ordinary skill in the art the time applicant’s invention was filed to use a fluid flow system configured to monitor/calculate a fluid flow rate during the surgical treatment to determine when ablation is complete. Surgical techniques to lower intraocular pressure, when medication fails to decrease fluid flow into the eye or to increase fluid outflow, include procedures that permit fluid to drain from within the eye to extraocular sites by creating a fluid passageway between the anterior chamber of the eye and the potential supra-scleral/sub-Tenon's space, or, alternatively, into or through the Canal of Schlemm (see, e.g., U.S. Pat. No. 4,846,172). Allowable Subject Matter Claims 5, 6, 10, 11 and 13 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to AHMED M FARAH whose telephone number is (571)272-4765. The examiner can normally be reached Mon - Fri. 9:30AM -10:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Niketa Patel can be reached at 571-272-4156. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AHMED M FARAH/Primary Examiner, Art Unit 3792
Read full office action

Prosecution Timeline

Sep 20, 2023
Application Filed
Apr 24, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12672914
DEVICE FOR REAL-TIME NON-CONTACT SKIN TEMPERATURE MEASUREMENT
2y 8m to grant Granted Jul 07, 2026
Patent 12661096
POWER CONTROL ARRANGEMENTS FOR SURGICAL INSTRUMENTS AND BATTERIES
3y 8m to grant Granted Jun 23, 2026
Patent 12653718
OPHTHALMOLOGICAL PATIENT INTERFACE
2y 8m to grant Granted Jun 16, 2026
Patent 12636190
LASER THERAPY FOR TREATMENT AND PREVENTION OF EYE DISEASES
2y 8m to grant Granted May 26, 2026
Patent 12629246
METHOD FOR PATTERNED PLASMA-MEDIATED MODIFICATION OF THE CRYSTALLINE LENS
2y 5m to grant Granted May 19, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
98%
With Interview (+19.0%)
3y 4m (~7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1330 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month